glp-1 receptor agonist and dpp-4 inhibitor combination not recommended Role of Inhibitors in Clinical Practice The mechanism of action of

Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece

There is also a more subtle risk worth knowing: the Pasqua 2025 trial reported two cases of euglycemic ketosis without acidosis in semaglutide-treated participants

Studies have shown that sitagliptin is a selective and potent inhibitor (greater than 80%) of the DPP-4 enzyme

This sales data dwarfs older products: for context, Lillys Humalog insulin now brings only a few hundred million per quarter

12 By embracing these strategies, individuals using GLP-1 medications can optimize their results, minimize discomfort, and build a foundation for a healthier, more empowered future